NCT06694389: An ongoing trial by ModernaTX, Inc.
This trial is ongoing. It must report results 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06694389 |
|---|---|
| Title | A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adults ≥50 Years of Age |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 18, 2024 |
| Completion date | Nov. 17, 2025 |
| Required reporting date | Nov. 17, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 15, 2026 |
| Days late | None |